Enovis CORP

Enovis Corporation's stockholders approved an amendment to the 2020 Omnibus Incentive Plan, authorizing additional shares and increasing director compensation limits at the May 19, 2026 Annual Meeting.

Enovis Corporation announced first-quarter 2026 results with net sales of $589 million, a 5% increase year-over-year, and reaffirmed its full-year financial outlook.

Enovis Corporation announced its fourth quarter and full year 2025 financial results, reporting significant sales growth but also a substantial non-cash goodwill impairment charge.

Enovis Corporation announced its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.

Enovis Corporation announced the retirement of Senior Vice President and Chief Human Resources Officer Patricia A. Lang, effective April 3, 2026, with Laura Singleton appointed as her successor.

Enovis Corporation has amended its credit agreement, extending the maturity date of its revolving and term loan facilities to December 8, 2030, and enhancing financial flexibility.

Enovis Corporation reported a net loss of $8.45 million for the first quarter of 2026, a significant improvement from the prior year's loss, driven by increased net sales and improved gross profit margins.

Enovis Corporation reported a significant net loss for the third quarter and nine months ended October 3, 2025, primarily driven by a $548.4 million non-cash goodwill impairment charge, despite strong sales growth in both segments.

Enovis Corporation reported increased net sales and Adjusted EBITDA in Q2 2025, but net loss expanded due to significant non-recurring charges and tax adjustments.

Enovis Corporation's Q1 2025 results show increased sales and adjusted EBITDA, alongside the announcement of Damien McDonald as the new CEO.

Enovis Corporation's Q3 2024 results show significant revenue growth driven by the Lima acquisition, but also increased expenses and a net loss.

Enovis Corporation's Q2 2024 results show significant revenue growth driven by the Lima acquisition, but also increased expenses and a net loss.

Enovis Corporation posted a significant net loss of $1.18 billion in 2025, primarily driven by substantial goodwill impairment charges, despite a 6.7% increase in net sales.

Enovis Corporation's 10-K filing reveals a year marked by strategic acquisitions and a significant goodwill impairment charge, impacting overall financial performance.

Enovis Corporation's 2023 annual report highlights its focus on medical technology, with growth in both Prevention & Recovery and Reconstructive segments, and strategic acquisitions.

Enovis Corp director Christine Ortiz acquired 846 shares of common stock on June 30, 2026, with no cost basis reported.

Chief Administrative Officer Oliver Engert purchased 1,000 shares of Enovis Corp common stock at $20.92 per share.

Chief Administrative Officer Oliver Engert filed an amendment to correct clerical errors regarding share acquisition data.

Chief Administrative Officer Oliver Engert purchased 1,200 shares of Enovis Corp common stock on June 11, 2026.

Chief Administrative Officer Oliver Engert acquired 1,000 shares of Enovis Corp common stock at a price of $23 per share.

Chief Administrative Officer Oliver Engert acquired 1,000 shares of Enovis Corporation common stock at $22.22 per share.

Enovis Corporation has issued its 2026 proxy statement, seeking stockholder approval for director elections, auditor ratification, executive compensation, and an amendment to its 2020 Omnibus Incentive Plan.

Enovis Corporation announces its 2025 Annual Meeting of Stockholders and provides information on how to access proxy materials and vote.

Enovis Corporation sets date for its 2025 Annual Meeting of Stockholders and announces the retirement of its CEO, Matthew L. Trerotola, and the appointment of Damien McDonald as his successor.

Enovis Corporation announces its 2024 Annual Meeting and provides details on voting for director elections, auditor ratification, executive compensation, and amendments to incentive plans and corporate charter.

Enovis Corporation's proxy statement details proposals for the upcoming annual meeting, including director elections, auditor ratification, executive compensation, and amendments to incentive plans and corporate charter.

American Century Capital Portfolios, Inc., American Century Investment Management, Inc., American Century Companies, Inc., and Stowers Institute for Medical Research have jointly filed a Schedule 13G, reporting beneficial ownership of Enovis Corporation common stock.

Vanguard Capital Management has filed a Schedule 13G reporting a 5.23% beneficial ownership stake in Enovis Corp.

Vanguard Portfolio Management has reported a beneficial ownership of 6.82% in Enovis Corp's common stock as of March 31, 2026.

The Vanguard Group has filed an amendment to its Schedule 13G for Enovis Corp, reporting zero beneficial ownership following an internal realignment.

Dimensional Fund Advisors LP filed an Amendment No. 2 to its Schedule 13G, reporting a 4.9% beneficial ownership in Enovis Corp's common stock as of December 31, 2025.

American Century Capital Portfolios, Inc. and its affiliates have filed an amended Schedule 13G, disclosing their beneficial ownership in Enovis Corporation's common stock.